A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)
Sponsor: Emergent BioSolutions
Terminated
Sponsor Decision
A PHASE1 clinical study on Adenoviral Infection, this trial is terminated or withdrawn. The trial is conducted by Emergent BioSolutions and has accumulated 8 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Apr 2024 [monthly]
Terminated PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 3 earlier versions
-
Jul 2018 — Apr 2020 [monthly]
Terminated PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emergent BioSolutions
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .